Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV(R) (telavancin), Including Ongoing TOUR(TM) Observational Patient Registry, at IDWeek 2016

DUBLIN, IRELAND--(Marketwired - Oct 18, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that data from new studies of VIBATIV^® (telavancin) will be presented at IDWeek^™ 2016, being held in New Orleans, LA on October 26 - 30, 2016. Researchers will present interim data from the first 200 patients enrolled in the Company's ongoing Telavancin Observational Use Registry (TOUR^™) study, highlighting clinical response rates and prescribing patterns for VIBATIV. TOUR is designed to assess how the antibiotic is being used by healthcare practitioners to treat patients in real-world clinical settings.

Additional presentations will include data from a retrospective analysis of VIBATIV in osteomyelitis patients and multiple studies of the in vitro potency of VIBATIV against several challenging pathogens as compared to other commercialized antibiotics. Researchers also will present findings from two company-sponsored retrospective analyses of data from the Company's previously completed Phase 3 ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies comparing the overall healthcare costs and renal function impact for VIBATIV as compared to vancomycin.

Details of the VIBATIV poster presentations at IDWeek 2016 are as follows:

Poster #1168:
The Telavancin Observational Use Registry (TOUR™): Methodology and Preliminary Clinical Experience

Viewing Time: Friday, October 28, 2016, 12:30 p.m. Eastern
Location: Poster Hall

Poster #1131:
Real-World Use of Telavancin in the Treatment of Osteomyelitis 

Viewing Time: Friday, October 28, 2016, 12:30 p.m. Eastern
Location: Poster Hall

Poster #1845:
Telavancin Displays Activity Against Cystic Fibrosis-associated MRSA Strains including those with Increased Resistance to Ceftaroline

Viewing Time: Saturday, October 29, 2016, 12:30 p.m. Eastern
Location: Poster Hall

Poster #1250:
Telavancin vs. Vancomycin in the Treatment of Hospital-Acquired Pneumonia Caused by S. Aureus: Decision Analytic Model

Viewing Time: Friday, October 28, 2016, 12:30 p.m. Eastern
Location: Poster Hall

Poster #1260:
Utility of Renal Shift Tables to Assess the Magnitude and Chronicity of Antibiotic-Associated Changes in Renal Function in Clinical Trials: Results from Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) trials for Telavancin and Vancomycin